Prenatal rapamycin results in early and late behavioral abnormalities in wildtype C57Bl/6 Mice

Peter T. Tsai, Emily Greene-Colozzi, June Goto, Stefanie Anderl, David J. Kwiatkowski, Mustafa Sahin

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

Mammalian target of rapamycin (mTOR) signaling has been shown to be deregulated in a number of genetic, neurodevelopmental disorders including Tuberous Sclerosis Complex, Neurofibromatosis, Fragile X, and Rett syndromes. As a result, mTOR inhibitors, such as rapamycin and its analogs, offer potential therapeutic avenues for these disorders. Some of these disorders - such as Tuberous Sclerosis Complex - can be diagnosed prenatally. Thus, prenatal administration of these inhibitors could potentially prevent the development of the devastating symptoms associated with these disorders. To assess the possible detrimental effects of prenatal rapamycin treatment, we evaluated both early and late behavioral effects of a single rapamycin treatment at embryonic day 16.5 in wildtype C57Bl/6 mice. This treatment adversely impacted early developmental milestones as well as motor function in adult animals. Rapamycin also resulted in anxiety-like behaviors during both early development and adulthood but did not affect adult social behaviors. Together, these results indicate that a single, prenatal rapamycin treatment not only adversely affects early postnatal development but also results in long lasting negative effects, persisting into adulthood. These findings are of importance in considering prenatal administration of rapamycin and related drugs in the treatment of patients with neurogenetic, neurodevelopmental disorders.

Original languageEnglish (US)
Pages (from-to)51-59
Number of pages9
JournalBehavior Genetics
Volume43
Issue number1
DOIs
StatePublished - Jan 2013

Fingerprint

sclerosis
Sirolimus
abnormality
adulthood
postnatal development
inhibitor
mice
genetic disorders
anxiety
social behavior
signs and symptoms (animals and humans)
drug therapy
early development
therapeutics
Tuberous Sclerosis
drug
Therapeutics
animal
Rett Syndrome
Fragile X Syndrome

Keywords

  • Embryonic
  • Mouse
  • mTOR
  • Tuberous sclerosis

ASJC Scopus subject areas

  • Genetics
  • Genetics(clinical)
  • Ecology, Evolution, Behavior and Systematics

Cite this

Prenatal rapamycin results in early and late behavioral abnormalities in wildtype C57Bl/6 Mice. / Tsai, Peter T.; Greene-Colozzi, Emily; Goto, June; Anderl, Stefanie; Kwiatkowski, David J.; Sahin, Mustafa.

In: Behavior Genetics, Vol. 43, No. 1, 01.2013, p. 51-59.

Research output: Contribution to journalArticle

Tsai, PT, Greene-Colozzi, E, Goto, J, Anderl, S, Kwiatkowski, DJ & Sahin, M 2013, 'Prenatal rapamycin results in early and late behavioral abnormalities in wildtype C57Bl/6 Mice', Behavior Genetics, vol. 43, no. 1, pp. 51-59. https://doi.org/10.1007/s10519-012-9571-9
Tsai, Peter T. ; Greene-Colozzi, Emily ; Goto, June ; Anderl, Stefanie ; Kwiatkowski, David J. ; Sahin, Mustafa. / Prenatal rapamycin results in early and late behavioral abnormalities in wildtype C57Bl/6 Mice. In: Behavior Genetics. 2013 ; Vol. 43, No. 1. pp. 51-59.
@article{056e753405ef4f5faeedf56e78a84994,
title = "Prenatal rapamycin results in early and late behavioral abnormalities in wildtype C57Bl/6 Mice",
abstract = "Mammalian target of rapamycin (mTOR) signaling has been shown to be deregulated in a number of genetic, neurodevelopmental disorders including Tuberous Sclerosis Complex, Neurofibromatosis, Fragile X, and Rett syndromes. As a result, mTOR inhibitors, such as rapamycin and its analogs, offer potential therapeutic avenues for these disorders. Some of these disorders - such as Tuberous Sclerosis Complex - can be diagnosed prenatally. Thus, prenatal administration of these inhibitors could potentially prevent the development of the devastating symptoms associated with these disorders. To assess the possible detrimental effects of prenatal rapamycin treatment, we evaluated both early and late behavioral effects of a single rapamycin treatment at embryonic day 16.5 in wildtype C57Bl/6 mice. This treatment adversely impacted early developmental milestones as well as motor function in adult animals. Rapamycin also resulted in anxiety-like behaviors during both early development and adulthood but did not affect adult social behaviors. Together, these results indicate that a single, prenatal rapamycin treatment not only adversely affects early postnatal development but also results in long lasting negative effects, persisting into adulthood. These findings are of importance in considering prenatal administration of rapamycin and related drugs in the treatment of patients with neurogenetic, neurodevelopmental disorders.",
keywords = "Embryonic, Mouse, mTOR, Tuberous sclerosis",
author = "Tsai, {Peter T.} and Emily Greene-Colozzi and June Goto and Stefanie Anderl and Kwiatkowski, {David J.} and Mustafa Sahin",
year = "2013",
month = "1",
doi = "10.1007/s10519-012-9571-9",
language = "English (US)",
volume = "43",
pages = "51--59",
journal = "Behavior Genetics",
issn = "0001-8244",
publisher = "Springer New York",
number = "1",

}

TY - JOUR

T1 - Prenatal rapamycin results in early and late behavioral abnormalities in wildtype C57Bl/6 Mice

AU - Tsai, Peter T.

AU - Greene-Colozzi, Emily

AU - Goto, June

AU - Anderl, Stefanie

AU - Kwiatkowski, David J.

AU - Sahin, Mustafa

PY - 2013/1

Y1 - 2013/1

N2 - Mammalian target of rapamycin (mTOR) signaling has been shown to be deregulated in a number of genetic, neurodevelopmental disorders including Tuberous Sclerosis Complex, Neurofibromatosis, Fragile X, and Rett syndromes. As a result, mTOR inhibitors, such as rapamycin and its analogs, offer potential therapeutic avenues for these disorders. Some of these disorders - such as Tuberous Sclerosis Complex - can be diagnosed prenatally. Thus, prenatal administration of these inhibitors could potentially prevent the development of the devastating symptoms associated with these disorders. To assess the possible detrimental effects of prenatal rapamycin treatment, we evaluated both early and late behavioral effects of a single rapamycin treatment at embryonic day 16.5 in wildtype C57Bl/6 mice. This treatment adversely impacted early developmental milestones as well as motor function in adult animals. Rapamycin also resulted in anxiety-like behaviors during both early development and adulthood but did not affect adult social behaviors. Together, these results indicate that a single, prenatal rapamycin treatment not only adversely affects early postnatal development but also results in long lasting negative effects, persisting into adulthood. These findings are of importance in considering prenatal administration of rapamycin and related drugs in the treatment of patients with neurogenetic, neurodevelopmental disorders.

AB - Mammalian target of rapamycin (mTOR) signaling has been shown to be deregulated in a number of genetic, neurodevelopmental disorders including Tuberous Sclerosis Complex, Neurofibromatosis, Fragile X, and Rett syndromes. As a result, mTOR inhibitors, such as rapamycin and its analogs, offer potential therapeutic avenues for these disorders. Some of these disorders - such as Tuberous Sclerosis Complex - can be diagnosed prenatally. Thus, prenatal administration of these inhibitors could potentially prevent the development of the devastating symptoms associated with these disorders. To assess the possible detrimental effects of prenatal rapamycin treatment, we evaluated both early and late behavioral effects of a single rapamycin treatment at embryonic day 16.5 in wildtype C57Bl/6 mice. This treatment adversely impacted early developmental milestones as well as motor function in adult animals. Rapamycin also resulted in anxiety-like behaviors during both early development and adulthood but did not affect adult social behaviors. Together, these results indicate that a single, prenatal rapamycin treatment not only adversely affects early postnatal development but also results in long lasting negative effects, persisting into adulthood. These findings are of importance in considering prenatal administration of rapamycin and related drugs in the treatment of patients with neurogenetic, neurodevelopmental disorders.

KW - Embryonic

KW - Mouse

KW - mTOR

KW - Tuberous sclerosis

UR - http://www.scopus.com/inward/record.url?scp=84872681250&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84872681250&partnerID=8YFLogxK

U2 - 10.1007/s10519-012-9571-9

DO - 10.1007/s10519-012-9571-9

M3 - Article

C2 - 23229624

AN - SCOPUS:84872681250

VL - 43

SP - 51

EP - 59

JO - Behavior Genetics

JF - Behavior Genetics

SN - 0001-8244

IS - 1

ER -